TFA
RNAM

Toth Financial Advisory’s Avidity Biosciences RNAM Stock Holding History

Toth Financial Advisory’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$1K – 761
2022
Q1 		$1K Hold
50
– – ﹤0.01% 682
2021
Q4 		$1K Hold
50
– – ﹤0.01% 714
2021
Q3 		$1K Hold
50
– – ﹤0.01% 725
2021
Q2 		$1K Hold
50
– – ﹤0.01% 665
2021
Q1 		$1K Buy
+50
New +$1.22K ﹤0.01% 649

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Toth Financial Advisory's RNAM Position: Q2 2022 in Review

Toth Financial Advisory sold out of Avidity Biosciences (RNAM) in Q2 2022, closing a stake of 50 shares — an estimated $1K sold.

Toth Financial Advisory first reported a position in RNAM in Q1 2021 and held it in 5 quarters. The position peaked at $1K in Q1 2022. 115 funds tracked by Wall St. Rank hold RNAM as of Q2 2022.

  • Toth Financial Advisory reported no remaining Avidity Biosciences position as of Q2 2022 after selling out during the quarter.
  • Toth Financial Advisory sold 50 Avidity Biosciences shares in Q2 2022, an estimated $1K.
  • Toth Financial Advisory first reported a position in Avidity Biosciences in Q1 2021 and held it in 5 quarters.
  • Toth Financial Advisory's Avidity Biosciences position peaked at $1K in Q1 2022.
  • 115 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2022.

Based on Toth Financial Advisory's 13F filing for Q2 2022, filed 25 Jul 2022.